Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a …
Read More
RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage pharmaceutical company, today announced it has filed an application with U.S. Food and Drug Administration (FDA) requesting Emergency Use …
Read More
WAYNE, PA — NFlection Therapeutics, Inc this week announced positive results from a 28-day, Phase 2a, multicenter, randomized, double-blind, parallel-group, vehicle-controlled clinical trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics …
Read More
WASHINGTON, D.C. — The following quote is attributed to William Maisel, M.D., chief medical officer and director of the Office of Product Evaluation and Quality in FDA’s Center for Devices …
Read More
WASHINGTON, D.C. — The following is attributed to Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health:
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy …
Read More
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, has provided an update on corporate …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has reported financial results for the first quarter …
Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the Company has received guidance from the …
Read More